Cardiovascular Peptides Market - Global Industry Analysis,Trends And Forecast 2015 – 2023

Transparency Market Research
Single User License:
Cardiovascular Peptides Market - Global
Industry Analysis, Size, Share, Growth,
Trends And Forecast 2015 - 2023
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
www.transparencymarketresearch.com
sales@transparencymarketresearch.com
USD 4315.5



Flat 10% Discount!!

Report will be delivered with in 15-20 working days
Free Customization as per your requirement
You will get Custom Report at Syndicated Report
price
Request Sample
Buy Now
REPORT DESCRIPTION
Transparency Market Research Reports incorporated a definite business overview and investigation inclines on Cardiovascular
Peptides Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2015 - 2023. This report
likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and
worldwide business sector industry structure.
Peptides are short chain of amino acids linked by peptide bonds. Usually they contain less than 50 amino acids. Natural
cardiovascular peptides such as ANP and BNP are hormones of cardiac origin that play an important role in the regulation of
cardiovascular homeostasis. Cardiovascular peptides are predominantly produced in heart, although many other tissues
produced it but in amounts inadequate to induce any physiological effects. Advancement in biotechnology and pharmaceutical
sciences has enable researchers to modify or mimic naturally occurring peptide for diverse therapeutic uses. One such example
is Nesiritide, recombinant form of the 32 amino acid human B-type natriuretic peptide. Cardiovascular peptides are used in
primarily to treat or avoid acute myocardial infarction, Coronary Ischemia, hypertension, Cardio metabolic Disease, heart failure,
peripheral vascular diseases, and hematologic diseases.
Browse Full Report With TOC : http://www.transparencymarketresearch.com/cardiovascular-peptides-market.html
Increasing prevalence of cardiovascular diseases obesity, sedentary lifestyle, serious side effects associated with currently
available cardiovascular products and high risk linked with surgical procedures are some major factors driving the cardiovascular
peptides market growth. As per the World Health Organization (WHO) statistics on cardiovascular diseases, approximately 17.3
million people died from cardiovascular diseases in 2008, accounting for nearly 30% of all global deaths. The WHO further states
that the number of global deaths by cardiovascular diseases is expected to reach 30 million by 2030. Concerted efforts in
research and development by pharmaceutical companies and extensive research collaborations would help them gain core
competencies in this market. Big pharmaceutical companies such as Eli Lilly & Company, Novo Nordisk, Novartis AG, and Bristol
Myers Squibb (BMS) have invested huge money in research and development of cardiovascular peptides. However, high cost
associated with development of cardiovascular peptides, strict regulatory policies and FDA approval procedure may impede
growth of the cardiovascular peptides market to some extent. Furthermore, availability of alternate treatment options is one of
the key challenges for global cardiovascular peptides market.
The cardiovascular peptides market has been analyzed on the basis of major cardiovascular diseases such as heart failure,
myocardial infarction, hypertension, peripheral vascular diseases and hematologic Diseases. Many of the cardiovascular
peptides are in clinical trials. Danegaptide, a novel dipeptide, invented by Zealand, is a potent and selective gap junction
modifier. Currently this drug is in the Phase II Proof-of-Concept study to evaluate the efficacy and safety in patients with an
acute myocardial infarction (AMI).
Enquiry Before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6263
Geographically, the global cardiovascular peptides market has been segmented into North America, Europe, Asia-Pacific and
Rest of World (RoW). North America dominates the global cardiovascular peptides market owning to high prevalence rate of
cardiovascular diseases, huge healthcare expenditure, insurance coverage and sophisticated diagnostic technologies for cardiac
manifestations. According to the American Heart Association, 650,000 new cases of cardiac diseases are diagnosed every year
in U.S. In Europe, cardiovascular diseases are most prevalent in Central and Eastern Europe. As per European Society of
Cardiology, in 2012, cardiovascular diseases accounted for 4 million deaths in Europe, nearly 47% of all deaths. In Asia-Pacific
region, particularly India and China are the fastest growing markets for cardiovascular peptide therapeutics owning to large
population base and increasing elderly population.
Some of the major players in cardiovascular peptides market include Eli Lilly & Company, Novo Nordisk, Novartis AG,
AstraZeneca, and plc, Bristol Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical, Zealand Pharma, Diartis Pharmaceuticals,
American Peptide Company, Inc., Capstone Therapeutics and Nile Therapeutics, Inc.
This research report analyzes this market on the basis of its market segments, major geographies, and current
market trends. This report provides comprehensive analysis of
•
Market growth drivers
•
Factors limiting market growth
•
Current market trends
•
Market structure
•
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market
projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis
and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the
existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
•
This report provides pin-point analysis for changing competitive dynamics
•
It provides a forward looking perspective on different factors driving or restraining market growth
•
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
•
It helps in understanding the key product segments and their future
•
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
•
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of
market segments
•
It provides distinctive graphics and exemplified SWOT analysis of major market segments
Read More Reports On Chemical Market : http://www.transparencymarketresearch.com/chemical-market-reports-2.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision
makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and
various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most
reliable information indispensable for businesses to sustain a competitive edge.
Latest Press Release Reports : http://www.transparencymarketresearch.com/press-releases.htm
Latest Articles Reports : http://www.transparencymarketresearch.com/articles.htm
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
Browse Market Research Blog : http://globalresearchanalysis.blogspot.in/

Peptides are short chain of amino acids linked by peptide bonds. Usually they contain less than 50 amino acids. Natural cardiovascular peptides such as ANP and BNP are hormones of cardiac origin that play an important role in the regulation of cardiovascular homeostasis. Cardiovascular peptides are predominantly produced in heart, although many other tissues produced it but in amounts inadequate to induce any physiological effects. Advancement in biotechnology and pharmaceutical sciences has enable researchers to modify or mimic naturally occurring peptide for diverse therapeutic uses. One such example is Nesiritide, recombinant form of the 32 amino acid human B-type natriuretic peptide. Cardiovascular peptides are used in primarily to treat or avoid acute myocardial infarction, Coronary Ischemia, hypertension, Cardio metabolic Disease, heart failure, peripheral vascular diseases, and hematologic diseases. Browse Report With Full TOC At : http://www.transparencymarketresearch.com/cardiovascular-peptides-market.html